Quantifying common adverse effects of a drug used for any indication from RCTs: the example of amoxicillin by Gillies, Malcolm et al.
Bond University
Research Repository
Quantifying common adverse effects of a drug used for any indication from RCTs: the
example of amoxicillin
Gillies, Malcolm; Ranakusuma, Anggi; Thorning, Sarah; Hoffmann, Tammy C; McGuire,






Link to publication in Bond University research repository.
Recommended citation(APA):
Gillies, M., Ranakusuma, A., Thorning, S., Hoffmann, T. C., McGuire, T. M., Glasziou, P. P., & Del Mar, C. B.
(2016). Quantifying common adverse effects of a drug used for any indication from RCTs: the example of
amoxicillin. Evidence Live Conference, Oxford, United Kingdom.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 18 Jun 2021
Quantifying common adverse
effects of a drug used for any
indication from RCTs: the example
of amoxicillin
Chris Del Mar










• antibiotic resistance crisis
• primary care focus
• need to reduce antibiotics for common ARIs
apart from resistance, antibiotic…
 …minimal benefit
 …have common harms
-- but poorly quantified
amoxicillin +/- clavulinate
why we did the review
antibiotic resistance
• tonnage antibiotics ¾ in primary care
• opportunity for shared decision making





how AEs are usually measured







– national AEs voluntary reporting













P – any patients for any indication
I – amoxicillin / co-amoxiclav
C – placebo
O – any adverse events (AEs)
search
what we did
• RCT for any indication
• MEDLINE; Embase; Cochrane CENTRAL
• placebo
search
• we discarded all but 45
(27 of amoxicillin and 17
co-amoxiclav)







only 25/45 trials harms data






















• RCTs poorly report AEs
• evidence of common AEs for amoxicillin (+/- clavulanate)
• co-amoxiclav diarrhoea ~ NNT =10, [95%CI 6-17]
• Amoxicillin + co-amoxiclav candida NNT = 27 [95%CI 24-42]
• if poor reporting, then gross under-estimate
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conclusions 2
• this method of quantifying AEs depends on
proper reporting in RCTs
• AEs reporting in RCTs must be improved
• data used in Decision Aids
• we are currently reviewing a new set of
antibiotics (macrolides and cephalosporins)
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